Search Results - "Pellicer Franco, C."

PP-043 Evolution of costs in biological intravenous treatments in rheumatic diseases over 5 years by Franco, C Pellicer, de la Rubia Nieto, A

“…BackgroundRheumatic diseases generate considerable consumption of health resources due to the use of biological therapies, continuous monitoring of disease and…”
Get full text

PP-045 Evaluation of compounding quality of intravenous admixtures by Luiz, A Tomás, Franco, C Pellicer, Jimenez, MDM Ruiz, Rivadeneyra, M Almanchel, Carmona, J Mateo, Nieto, MA de La Rubia

“…BackgroundAccording to guides, it is necessary to ensure the compounding quality of intravenous admixtures in the pharmacy service.PurposeTo evaluate the…”
Get full text

Phytosterols: Why should we concern about it? Liver impairment in adult patients with parenteral nutrition: Multicenter prospective study by Berlana, D., Mercadal Orfila, G., Murcia, A.C., Montañés Pauls, B., Pellicer Franco, C., Castellano Copa, P., Ripa Ciaurriz, C., Lago Rivero, N., Cuesta Grueso, C., Espla Gonzalez, S., Puertas Sanjuan, A., Nebot Meneu, P., Lluch Taltavull, J., De Pourcq, J.T., Chica Marchal, A.

Get full text

Observational study of the efficacy and tolerability of bosentan for the treatment of pulmonary hypertension in a tertiary referral hospital by Pellicer Franco, C, Iglesias Neiro, P, Piñeiro Corrales, G

“…The pathogenesis of pulmonary hypertension (PHT) involves elevated levels of endothelin. Bosentan is a receptor antagonist used for the treatment of this…”
Get full text

Estudio observacional sobre la efectividad y tolerabilidad del bosentán en el tratamiento de la hipertensión pulmonar en un hospital general de tercer nivel by Pellicer Franco, C., Iglesias Neiro, P., Piñeiro Corrales, G.

“…La hipertensión pulmonar (HTP) es una enfermedad en cuya patogénesis está implicado un aumento de los niveles de endotelina. Bosentán es un antagonista de sus…”
Get full text